- Previous Close
806.55 - Open
819.90 - Bid --
- Ask --
- Day's Range
817.70 - 856.00 - 52 Week Range
757.05 - 1,639.00 - Volume
2,615,773 - Avg. Volume
930,602 - Market Cap (intraday)
149.834B - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
8.03 - EPS (TTM)
104.13 - Earnings Date May 26, 2025 - May 30, 2025
- Forward Dividend & Yield 7.25 (0.90%)
- Ex-Dividend Date Feb 18, 2025
- 1y Target Est
1,099.33
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
www.natcopharma.co.in4,016
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: NATCOPHARM.NS
View MorePerformance Overview: NATCOPHARM.NS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NATCOPHARM.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NATCOPHARM.NS
View MoreValuation Measures
Market Cap
144.43B
Enterprise Value
121.88B
Trailing P/E
7.75
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.39
Price/Book (mrq)
2.02
Enterprise Value/Revenue
2.86
Enterprise Value/EBITDA
4.94
Financial Highlights
Profitability and Income Statement
Profit Margin
43.58%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
42.8B
Net Income Avi to Common (ttm)
18.65B
Diluted EPS (ttm)
104.13
Balance Sheet and Cash Flow
Total Cash (mrq)
24.63B
Total Debt/Equity (mrq)
2.91%
Levered Free Cash Flow (ttm)
--